IDEAYA Biosciences, Inc. (IDYA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

IDEAYA Biosciences, Inc. (IDYA) Healthcare & Pipeline Overview

IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine oncology company, discovering and developing targeted therapeutics. Their pipeline includes inhibitors targeting various cancer pathways, positioning them in the competitive biotechnology sector with strategic collaborations with Pfizer and GlaxoSmithKline.

What Is the Investment Thesis for IDYA?

IDEAYA Biosciences presents a notable research candidate within the precision oncology space. The company's focus on synthetic lethality offers a targeted approach to cancer treatment, potentially leading to more effective therapies with fewer side effects. Key value drivers include the advancement of IDE397 and IDE196 through clinical trials, with potential data readouts in the next 12-18 months. The collaborations with Pfizer and GlaxoSmithKline provide validation of IDEAYA's technology and access to resources for further development. However, the company operates in a high-risk, high-reward environment, and clinical trial outcomes and regulatory approvals are uncertain. The company's high gross margin of 99.5% indicates strong pricing power if products reach the market, but the negative profit margin of -62.2% highlights the significant R&D expenses typical of biotechnology companies.

Based on FMP financials and quantitative analysis

IDYA Key Highlights

Market Cap of $3.56B reflects investor confidence in IDEAYA's pipeline and strategic partnerships.

• Gross Margin of 99.5% indicates potential for high profitability upon successful commercialization of drug candidates.
• Beta of 0.02 suggests low volatility compared to the overall market, potentially appealing to risk-averse investors.
• Strategic partnerships with Pfizer and GlaxoSmithKline provide access to resources and expertise, de-risking development.
• Focus on synthetic lethality offers a targeted approach to cancer treatment, potentially leading to more effective therapies.

Who Are IDYA's Competitors?

IDYA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are IDYA's Key Strengths?

Proprietary synthetic lethality platform.

• Strong intellectual property portfolio.
• Strategic partnerships with Pfizer and GlaxoSmithKline.
• Experienced management team.

What Are IDYA's Weaknesses?

Limited number of approved products.

• Reliance on clinical trial success.
• High R&D expenses.
• Negative profit margin.

What Could Drive IDYA Stock Higher?

Data readouts from Phase I clinical trial of IDE397 in MTAP-deleted solid tumors (2027).

• Data readouts from Phase I/II clinical trial of IDE196 in GNAQ/GNA11 mutant cancers (2027).
• IND-enabling studies for Pol Theta inhibitor program (2027).
• Clinical trial collaboration with Pfizer for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors.
• Strategic partnership with GlaxoSmithKline plc for drug discovery and development.

What Are the Key Risks for IDYA?

Negative return on equity (-14.0%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for IDE397 and IDE196.
• Regulatory delays or rejection of drug candidates.
• Competition from other biotechnology companies developing similar therapies.
• High R&D expenses impacting profitability.
• Dependence on strategic partnerships for funding and development.

What Are the Growth Opportunities for IDYA?

• IDE397 Development: IDEAYA has the opportunity to expand the clinical development of IDE397, a MAT2A inhibitor, beyond MTAP-deleted solid tumors. Exploring its efficacy in other cancer types with dysregulation of the methionine metabolism pathway could significantly broaden its market potential. The market for MAT2A inhibitors is estimated to reach $1 billion by 2030, driven by the increasing prevalence of MTAP-deleted cancers. Clinical trial results expected in 2027 will be a key milestone.
• IDE196 Expansion: IDEAYA can explore the potential of IDE196, a PKC inhibitor, in treating other genetically defined cancers beyond GNAQ or GNA11 mutations. Identifying additional patient populations with similar pathway dependencies could expand its therapeutic applications. The market for PKC inhibitors in oncology is projected to reach $800 million by 2028, fueled by the growing understanding of PKC's role in cancer signaling. Results from ongoing Phase I/II trials will inform future development strategies.
• PARG Inhibitor Program: IDEAYA's preclinical PARG inhibitor program represents a significant growth opportunity. Developing a PARG inhibitor for tumors with specific biomarkers based on genetic mutations and/or molecular signatures could address a substantial unmet need. The market for PARG inhibitors is estimated to reach $500 million by 2029, driven by the increasing adoption of personalized medicine approaches. Preclinical data expected in 2026 will determine the program's advancement.
• Pol Theta Inhibitor Program: The Pol Theta inhibitor program targeting tumors with BRCA or other homologous recombination deficiency mutations offers another avenue for growth. This approach capitalizes on the synthetic lethality principle, targeting a specific vulnerability in cancer cells. The market for Pol Theta inhibitors is projected to reach $700 million by 2030, driven by the increasing prevalence of BRCA mutations in various cancers. IND-enabling studies are planned for 2027.
• Strategic Partnerships: IDEAYA can continue to leverage strategic partnerships with pharmaceutical companies like Pfizer and GlaxoSmithKline to accelerate the development and commercialization of its pipeline. These collaborations provide access to resources, expertise, and global markets, enhancing IDEAYA's growth prospects. The value of strategic partnerships in the oncology space is estimated to reach $10 billion annually by 2028, reflecting the increasing need for collaboration to bring innovative therapies to market. Ongoing collaborations will continue to drive value.

What Opportunities Does IDYA Have?

• Expansion of pipeline through internal discovery and partnerships.
• Advancement of drug candidates through clinical trials.
• Commercialization of approved products.
• Expansion into new therapeutic areas.

What Are IDYA's Competitive Advantages?

• Proprietary drug discovery platform focused on synthetic lethality.
• Strong intellectual property portfolio protecting drug candidates and technologies.
• Strategic collaborations with leading pharmaceutical companies.
• Expertise in molecular diagnostics and personalized medicine.

What Does IDYA Do?

IDEAYA Biosciences, Inc., founded in 2015 and headquartered in South San Francisco, California, is a biotechnology company specializing in precision medicine oncology with a focus on synthetic lethality. The company is dedicated to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach involves identifying specific genetic vulnerabilities in cancer cells and developing drugs that exploit these weaknesses to selectively kill cancer cells while sparing healthy tissue. Their lead product candidates include IDE397, a methionine adenosyltransferase 2a (MAT2A) inhibitor currently in Phase I clinical trials for solid tumors with methylthioadenosine phosphorylase (MTAP) deletions. Another key candidate is IDE196, a protein kinase C (PKC) inhibitor in Phase I/II clinical trials for genetically defined cancers harboring GNAQ or GNA11 gene mutations. The company's preclinical pipeline features synthetic lethality programs targeting PARG inhibitors in tumors with defined biomarkers, Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations, and WRN inhibitors in tumors with high microsatellite instability (MSI). IDEAYA has established research collaborations with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase (PARG). They also have a clinical trial collaboration and supply agreement with Pfizer Inc. for a Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, along with a strategic partnership with GlaxoSmithKline plc.

What Products and Services Does IDYA Offer?

• Discovers and develops targeted cancer therapies.
• Focuses on synthetic lethality to selectively kill cancer cells.
• Utilizes molecular diagnostics to identify patient populations.
• Develops inhibitors for specific cancer pathways.
• Conducts preclinical and clinical trials to evaluate drug candidates.
• Collaborates with pharmaceutical companies and research institutions.

How Does IDYA Make Money?

• Develops proprietary drug candidates targeting specific cancer vulnerabilities.
• Out-licenses or co-develops drug candidates with pharmaceutical partners.
• Generates revenue through milestone payments and royalties from partnered programs.
• Funds research and development through venture capital and public offerings.

What Industry Does IDYA Operate In?

IDEAYA Biosciences operates in the rapidly evolving biotechnology industry, specifically within the precision oncology segment. The market for targeted cancer therapies is experiencing significant growth, driven by advances in genomics and personalized medicine. The competitive landscape includes companies like COGT: Cogent Biosciences, Inc., CDTX: Cidara Therapeutics, Inc., SRRK: Scholar Rock Holding Corporation, KNSA: Kiniksa Pharmaceuticals, Ltd., and LEGN: Legend Biotech Corporation, each pursuing different approaches to cancer treatment. IDEAYA's focus on synthetic lethality differentiates it from some competitors, offering a unique approach to targeting cancer cells.

Who Are IDYA's Key Customers?

• Patients with genetically defined cancers.
• Pharmaceutical companies seeking innovative cancer therapies.
• Healthcare providers prescribing targeted cancer treatments.
• Research institutions collaborating on drug discovery and development.

IDEAYA Biosciences, Inc. (IDYA) Valuation Context

Valued at $3.56B, IDYA is classified as a mid-cap stock. Analyst price targets span from $48.00 to $63.00, with a consensus of $57.00. At the current price of $37.45, that implies approximately 52% upside potential. Relative to its peer group, IDYA's quantitative score of 28/100 is below the peer average of 60/100.

IDYA Revenue & Earnings Trend

In Q2 FY2026, IDYA generated $8.9M in top-line revenue, marking a sequential increase of 35.0%. The company recorded a net loss of $112.5M, with diluted EPS of $-1.22. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, IDYA averaged $-0.49 in diluted EPS.

Company Profile

IDEAYA Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Yujiro S. Hata. IDYA has traded publicly since 2019.

Return on equity for IDEAYA Biosciences, Inc. stands at -14.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.2%, the inverse of the P/E and a quick read on earnings relative to price.

IDEAYA Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 19.08 places it in the safe zone, indicating low near-term bankruptcy risk.

IDEAYA Biosciences, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 12.3% above estimates on average.

Over the past six months, IDEAYA Biosciences, Inc. insiders filed 9 SEC Form 4 transactions — 2 sales and 7 purchases. On net that is roughly 110K shares acquired (about $3.3M) — insiders putting money in tends to read as conviction.

IDYA Financials

IDYA Latest News

IDYA Analyst Consensus

IDYA MoonshotScore

What Investors Ask About IDEAYA Biosciences, Inc. (IDYA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources